{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:36:48Z","timestamp":1772113008040,"version":"3.50.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":1400,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1136\/esmoopen-2017-000208","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T20:10:24Z","timestamp":1505506224000},"page":"e000208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment"],"prefix":"10.1016","volume":"2","author":[{"given":"DianaP","family":"Saraiva","sequence":"first","affiliation":[]},{"given":"M.","family":"Guadalupe Cabral","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Jacinto","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Braga","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2017-000208_bb0010","author":"World Health Organization","year":"2009","journal-title":"Women and health: today\u2019s evidence tomorrow\u2019s agenda"},{"key":"10.1136\/esmoopen-2017-000208_bb0015","series-title":"SEER Cancer Statistics Review, 1975-2012","author":"Howlader","year":"2015"},{"key":"10.1136\/esmoopen-2017-000208_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-008-0002-9","article-title":"Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence","volume":"114","author":"Marques","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0025","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1136\/esmoopen-2017-000208_bb0035","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ajpath.2013.05.033","article-title":"Triple-negative breast cancer and the need for new therapeutic targets","volume":"183","author":"Engebraaten","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1136\/esmoopen-2017-000208_bb0040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"15 Pt 1","key":"10.1136\/esmoopen-2017-000208_bb0050","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1-2","key":"10.1136\/esmoopen-2017-000208_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin Med Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0060","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdn675","article-title":"Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland","volume":"20","author":"Spitale","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000208_bb0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdm522","article-title":"MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer","volume":"19","author":"Eralp","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-007-9796-0","article-title":"alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer","volume":"111","author":"Ivanov","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0080","article-title":"Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations","volume":"14","author":"Wysocki","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1136\/esmoopen-2017-000208_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000208_bb0090","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2017-000208_bb0095","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2165-7386.1000270","article-title":"Decreased survival in African patients with triple negative breast cancer","volume":"06","author":"Honorio","year":"2016","journal-title":"J Palliat Care Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-9926-3","article-title":"Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA","volume":"113","author":"Lund","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0115","first-page":"75","article-title":"Experience with breast cancer in Zimbabwe","volume":"38","author":"Muguti","year":"1993","journal-title":"J R Coll Surg Edinb"},{"key":"10.1136\/esmoopen-2017-000208_bb0120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-008-0096-0","article-title":"Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients","volume":"115","author":"Yin","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0125","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08645","article-title":"Complex landscapes of somatic rearrangement in human breast cancer genomes","volume":"462","author":"Stephens","year":"2009","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000208_bb0135","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1055-9965.EPI-04-0394","article-title":"A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors","volume":"14","author":"Collett","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/esmoopen-2017-000208_bb0140","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1056\/NEJMicm063760","article-title":"Images in clinical medicine. Rapid progression of basal-type breast cancer","volume":"356","author":"Seewaldt","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0145","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1055-9965.EPI-08-0544","article-title":"Triple-negative breast cancer and obesity in a rural Appalachian population","volume":"17","author":"Vona-Davis","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0150","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/0008-5472.SABCS-09-6159","article-title":"Predominance of brain and lung metastases in triple-negative breast cancer patients","volume":"69","author":"Gadiyaram","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-006-9184-1","article-title":"Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer","volume":"99","author":"Pinilla","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0160","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1078-0432.CCR-05-2281","article-title":"Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas","volume":"12","author":"Rodr\u00edguez-Pinilla","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0165","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1158\/0008-5472.SABCS-09-3072","article-title":"Triple negative breast cancer patients with brain metastasis are associated with more concurrent lung metastases","volume":"69","author":"Tsang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0170","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.humpath.2008.05.010","article-title":"Bone metastasis is strongly associated with estrogen receptor-positive\/progesterone receptor-negative breast carcinomas","volume":"39","author":"Wei","year":"2008","journal-title":"Hum Pathol"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0175","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/0008-5472.SABCS-09-4044","article-title":"Triple negative breast cancer has a worse prognosis within 3 years after treatment compared to non-triple negative breast cancer","volume":"69","author":"Lee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2559.2009.03400.x","article-title":"Breast cancer in the elderly: a histological assessment","volume":"55","author":"Tse","year":"2009","journal-title":"Histopathology"},{"key":"10.1136\/esmoopen-2017-000208_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1470-2045(07)70042-6","article-title":"Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study","volume":"8","author":"Gong","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0190","first-page":"599","article-title":"The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients","volume":"100","author":"Crowe","year":"1986","journal-title":"Surgery"},{"key":"10.1136\/esmoopen-2017-000208_bb0195","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L","article-title":"Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons","volume":"56","author":"Natarajan","year":"1985","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0200","first-page":"69","article-title":"Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment","volume":"16","author":"Swanson","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1136\/esmoopen-2017-000208_bb0205","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina breast cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/esmoopen-2017-000208_bb0210","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2008.19.6873","article-title":"Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer","volume":"27","author":"Huo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0215","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1158\/0008-5472.SABCS-09-6045","article-title":"The triple threat of recurrence after breast conserving therapy: race, receptor status and age","volume":"69","author":"Zaky","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/bcr2242","article-title":"Triple-negative breast cancers are increased in black women regardless of age or body mass index 1","volume":"11","author":"Stead","year":"2009","journal-title":"Breast Cancer Research"},{"key":"10.1136\/esmoopen-2017-000208_bb0225","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm.2000","article-title":"Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers","volume":"15","author":"Lim","year":"2009","journal-title":"Nat Med"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0230","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1158\/0008-5472.SABCS-09-4065","article-title":"Clinicopathologic Signature of TNBC Patients with Good Prognosis","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res"},{"issue":"24 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0235","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/0008-5472.SABCS-09-3071","article-title":"The Epidemiology, Clinico-Pathologic and Prognostic Characteristics of Triple-Negative Breast Cancer Compared with Non Triple-Negative Breast Cancer","volume":"69","author":"Kwong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12282-008-0042-3","article-title":"Is triple negative a prognostic factor in breast cancer?","volume":"15","author":"Nishimura","year":"2008","journal-title":"Breast Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0245","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdn748","article-title":"Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer","volume":"20","author":"Frasci","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(09)70012-7","article-title":"Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept","volume":"45 Suppl 1","author":"Linn","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100937","article-title":"Evidence that breast tissue stiffness is associated with risk of breast cancer","volume":"9","author":"Boyd","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000208_bb0265","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","article-title":"Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis","volume":"15","author":"McCormack","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/esmoopen-2017-000208_bb0270","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djj331","article-title":"Prospective breast cancer risk prediction model for women undergoing screening mammography","volume":"98","author":"Barlow","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0275","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jnci\/djp175","article-title":"Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group","volume":"101","author":"Albain","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0280","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jnci\/dji064","article-title":"Ethnicity and breast cancer: factors influencing differences in incidence and outcome","volume":"97","author":"Chlebowski","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071915","article-title":"Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy","volume":"8","author":"Lindner","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000208_bb0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.23350","article-title":"The Wnt\/\u03b2-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer","volume":"113","author":"King","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1136\/esmoopen-2017-000208_bb0295","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/emmm.201201320","article-title":"WNT10B\/\u03b2-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer","volume":"5","author":"Wend","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0300","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bjc.6605488","article-title":"Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer","volume":"102","author":"Nalwoga","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0305","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0310","first-page":"LBA515","article-title":"Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007\/150012, ACRIN 6657)","author":"Esserman","year":"2009","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1136\/esmoopen-2017-000208_bb0315","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0320","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djn089","article-title":"Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0325","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0330","first-page":"255","article-title":"Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer","volume":"36","author":"Wang","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1136\/esmoopen-2017-000208_bb0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0340","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0345","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"H\u00fcsemann","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2017-000208_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/path.2629","article-title":"The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type","volume":"220","author":"Weigelt","year":"2010","journal-title":"J Pathol"},{"key":"10.1136\/esmoopen-2017-000208_bb0360","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0365","unstructured":"ClinicalTrials.gov. Bevacizumab + paclitaxel + capecitabine in triple negative metastatic breast cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01069796."},{"key":"10.1136\/esmoopen-2017-000208_bb0370","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.1000","article-title":"TITAN: Phase III study of doxorubicin\/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC)","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0375","unstructured":"ClinicalTrials.gov. Randomized phase II study of ixabepilone alone and ixabepilone plus cetuximab as first-line treatment for female subjects with triple negative locally advanced non-resectable and\/or metastatic breast cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00633464."},{"key":"10.1136\/esmoopen-2017-000208_bb0380","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA4","article-title":"OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)","volume":"35","author":"Robson","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2017-000208_bb0385","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2017-000208_bb0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.1982.170","article-title":"Mean nuclear area and histological grade of axillary-node tumour in breast cancer, related to prognosis","volume":"46","author":"Maehle","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/bjc.1990.152","article-title":"DNA index, S-phase fraction, histological grade and prognosis in breast cancer","volume":"61","author":"O\u2019Reilly","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0400","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/dji172","article-title":"Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute","volume":"97","author":"Hance","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2017-000208_bb0405","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","article-title":"Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer","volume":"120","author":"Jung","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0410","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"10.1136\/esmoopen-2017-000208_bb0415","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/cncr.24334","article-title":"Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer","volume":"115","author":"Rizzo","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0420","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrc2212","article-title":"Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis","volume":"7","author":"Stingl","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0425","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0430","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tem.2004.05.011","article-title":"Breast cancer, stem\/progenitor cells and the estrogen receptor","volume":"15","author":"Dontu","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1136\/esmoopen-2017-000208_bb0435","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1073\/pnas.0711613105","article-title":"BRCA1 regulates human mammary stem\/progenitor cell fate","volume":"105","author":"Liu","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/esmoopen-2017-000208_bb0440","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat Genet"},{"key":"10.1136\/esmoopen-2017-000208_bb0445","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.stem.2009.08.007","article-title":"Getting to the root of BRCA1-deficient breast cancer","volume":"5","author":"Ginestier","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1136\/esmoopen-2017-000208_bb0450","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2009.12.007","article-title":"Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content","volume":"140","author":"Pece","year":"2010","journal-title":"Cell"},{"key":"10.1136\/esmoopen-2017-000208_bb0455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.breast.2011.09.006","article-title":"Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design","volume":"21","author":"Eiermann","year":"2012","journal-title":"Breast"},{"key":"10.1136\/esmoopen-2017-000208_bb0460","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0465","first-page":"508","article-title":"Prevalence of BRCA1 mutations in triple negative breast cancer (BC)","author":"Kandel","year":"2006","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1136\/esmoopen-2017-000208_bb0470","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2009.07.011","article-title":"Targeting the molecular defect in BRCA-deficient tumors for cancer therapy","volume":"16","author":"Venkitaraman","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2017-000208_bb0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0485","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O\u2019Shaughnessy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0490","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0495","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0500","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/ol.2012.1093","article-title":"Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis","volume":"5","author":"Liu","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1136\/esmoopen-2017-000208_bb0505","article-title":"Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2017-000208_bb0510","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0515","first-page":"10","article-title":"Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer","volume":"7","author":"Liakou","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1136\/esmoopen-2017-000208_bb0520","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1136\/esmoopen-2017-000208_bb0525","first-page":"2064","article-title":"Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer","volume":"5","author":"Teng","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0530","first-page":"13","article-title":"T-lymphocyte subsets in primary lung cancer","volume":"17","author":"Tsuyuguchi","year":"1987","journal-title":"Jpn J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0535","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.1974.233","article-title":"Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review","volume":"30","author":"Underwood","year":"1974","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0540","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-12-30","article-title":"Tumor infiltrating B-cells are increased in prostate cancer tissue","volume":"12","author":"Woo","year":"2014","journal-title":"J Transl Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0545","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.4049\/jimmunol.0803107","article-title":"Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies","volume":"182","author":"Tuaillon","year":"2009","journal-title":"J Immunol"},{"issue":"9 Supplement","key":"10.1136\/esmoopen-2017-000208_bb0550","doi-asserted-by":"crossref","first-page":"PD1-3","DOI":"10.1158\/1538-7445.SABCS14-PD1-3","article-title":"Abstract PD1-3: The significance of tumor infiltrating lymphocyte density, subset composition and organization in breast cancer","volume":"75","author":"Willard-Gallo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","article-title":"The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy","volume":"220","author":"Apetoh","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000208_bb0560","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"10.1136\/esmoopen-2017-000208_bb0565","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0570","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/07357900802098165","article-title":"Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma","volume":"26","author":"Hornychova","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1136\/esmoopen-2017-000208_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115103","article-title":"The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis","volume":"9","author":"Mao","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000208_bb0580","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0585","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0590","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"4","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0595","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.humpath.2011.12.013","article-title":"Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer","volume":"43","author":"Yamaguchi","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1136\/esmoopen-2017-000208_bb0600","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0605","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr3148","article-title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1136\/esmoopen-2017-000208_bb0610","doi-asserted-by":"crossref","first-page":"no","DOI":"10.1111\/j.1365-2559.2011.03846.x","article-title":"Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade","volume":"58","author":"Baker","year":"2011","journal-title":"Histopathology"},{"key":"10.1136\/esmoopen-2017-000208_bb0615","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079775","article-title":"Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial","volume":"8","author":"Issa-Nummer","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2017-000208_bb0625","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/1471-2407-10-604","article-title":"Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules","volume":"10","author":"Teschendorff","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0630","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/0284186X.2012.731520","article-title":"Prognostic impact of FOXP3 expression in triple-negative breast cancer","volume":"52","author":"Lee","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0635","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","article-title":"Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1136\/esmoopen-2017-000208_bb0640","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/esmoopen-2017-000208_bb0645","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.2147\/OTT.S108419","article-title":"The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis","volume":"9","author":"Wei","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1136\/esmoopen-2017-000208_bb0650","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"Markowitz","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2017-000208_bb0655","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0660","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","article-title":"Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells","volume":"33","author":"Inozume","year":"2010","journal-title":"J Immunother"},{"key":"10.1136\/esmoopen-2017-000208_bb0665","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","article-title":"The evolution of checkpoint blockade as a cancer therapy: what\u2019s here, what\u2019s next?","volume":"33","author":"Shin","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/esmoopen-2017-000208_bb0670","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2017-000208_bb0675","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2017-000208_bb0680","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000208_bb0685","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000208_bb0690","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2017-000208_bb0695","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"10.1136\/esmoopen-2017-000208_bb0700","first-page":"31","article-title":"Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting","volume":"10","author":"Garc\u00eda-Teijido","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0705","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.556","article-title":"Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173","volume":"35","author":"Schmid","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0710","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.506","article-title":"Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2","volume":"35","author":"Nanda","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0715","article-title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A","volume":"35","author":"Adams","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0720","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.1007","article-title":"Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1\/2 mutations (ABRAZO)","volume":"35","author":"Turner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0725","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2015.33.15_suppl.tps1107","article-title":"A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and\/or metastatic breast cancer (EMBRACA","volume":"33","author":"Litton","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0730","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS591","article-title":"PARTNER: Randomised, phase II\/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and\/or germline BRCA mutated breast cancer patients","volume":"35","author":"Earl","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0735","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS595","article-title":"A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant:","volume":"35","author":"Litton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0740","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0745","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000208_bb0750","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-017-4336-z","article-title":"Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study","volume":"165","author":"Vernieri","year":"2017","journal-title":"Breast Cancer Res Treat"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2017-000208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:20:24Z","timestamp":1761855624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920323954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["S2059702920323954"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000208","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000208"}}